an-improved-continuous-suturing-technique-using-suture-hook-for

An Improved Continuous Suturing Technique Using a Suture Hook for Subscapularis Repair

Subscapularis tendon injuries often pose substantial challenges in arthroscopic repair, with traditional techniques frequently limited by prolonged ...

Objectives.  De qi is the subjective constellation of sensations perceived by the acupuncturists and patients as described in several literatures, but the absence of quantitative evaluation methods in de qi restricts the use of acupuncture treatment widely in the world. In the present study, we tried to investigate the intrinsic property of de qi is and how evaluate it quantitatively. Methods. 30 healthy adult volunteers were determined to investigate intrinsic changes in the human body after acupuncture with de qi. Results. Acupuncture treatment with de qi apparently increased acupoint blood flow, tissue displacement, and the amplitude of myoelectricity after de qi on acupoints. Furthermore, acupuncture treatment induced fMRI signal increase/decrease in different brain regions although no significant change in electroencephalography. Interpretation. The intrinsic change of the subjects representing the specific response of acupoints and human brain to acupuncture indicated that de qi might be evaluated quantitatively by those above aspects, which facilitated the confirmation in validity and propagation of this treatment modality widely in the world. 

De qi, a threshold of the stimulus intensity, elicits the specific response of acupoints and intrinsic change of human brain to acupuncture.

The neuroendocrine tumor (NET) is rare, accounting for about 0.5% of all tumors. NETs have the characteristics of metastasis, especially lymph nodes, liver, spleen, and bone.

Rare Bone Metastasis of Neuroendocrine Tumors of Unknown Origin: A Case Report and Literature Review.

The importance of reactive oxygen species (ROS) in the occurrence and development of orthopaedic related diseases is becoming increasingly prominent. ROS regulation has become a new method to treat orthopaedic related diseases. In recent years, the application of nanomaterials has become a new hope for precision and efficient treatment. However, there is a lack of reviews on ROS-regulated nanomaterials for orthopaedic related diseases. Based on the key significance of nanomaterials for the treatment of orthopaedic related diseases, we searched the latest related studies and reviewed the nanomaterials that regulate ROS in the treatment of orthopaedic related diseases. According to the function of nanomaterials, we describe the scavenging of ROS related nanomaterials and the generation of ROS related nanomaterials. In this review, we closely integrated nanomaterials with the treatment of orthopaedic related diseases such as arthritis, osteoporosis, wound infection and osteosarcoma, , and highlighted the advantages and disadvantages of existing nanomaterials. We also looked forward to the design of ROS-regulated nanomaterials for the treatment of orthopaedic related diseases in the future.

Application and prospect of ROS-related nanomaterials for orthopaedic related diseases treatment.

Bone metastases, as one of the common types of metastatic tumors, have a great impact on the survival period and quality of life of patients. Bone metastases are usually characterized by bone destruction. Skeletal related events caused by bone destruction often lead to pain, pathological fractures and even paralysis. In this review, we provide a detailed explanation of bone metastases from the epidemiology, clinical features, pathogenesis, and recently developed clinical treatment viewpoints. We concluded that the incidence of bone metastases is increasing gradually, with serious clinical symptoms, complex pathogenesis and diverse clinical treatment. Tumor cells, immune cells, osteoblasts/osteoclasts and other cells as well as cytokines and enzymes all play a key role in the pathogenesis of bone metastases. We believe that the future treatment of bone metastases will be diversified and comprehensive. Some advanced technologies, such as nanomedicine, could be used for treatment, but this depends on understanding how disease occurs. With the development of treatment, the survival time and quality of life of patients will be improved.

Research progress of bone metastases: From disease recognition to clinical practice.

The progressive worsening of disc degeneration and related nonspecific back pain are prominent clinical issues that cause a tremendous economic burden. Activation of reactive oxygen species (ROS) related inflammation is a primary pathophysiologic change in degenerative disc lesions. This pathological state is associated with M1 macrophages, apoptosis of nucleus pulposus cells (NPC), and the ingrowth of pain-related sensory nerves. To address the pathological issues of disc degeneration and discogenic pain, we developed MnO@TMNP, a nanomaterial that encapsulated MnO nanoparticles with a TrkA-overexpressed macrophage cell membrane (TMNP). Consequently, this engineered nanomaterial showed high efficiency in binding various inflammatory factors and nerve growth factors, which inhibited inflammation-induced NPC apoptosis, matrix degradation, and nerve ingrowth. Furthermore, the macrophage cell membrane provided specific targeting to macrophages for the delivery of MnO nanoparticles. MnO nanoparticles in macrophages effectively scavenged intracellular ROS and prevented M1 polarization. Supportively, we found that MnO@TMNP prevented disc inflammation and promoted matrix regeneration, leading to downregulated disc degenerative grades in the rat injured disc model. Both mechanical and thermal hyperalgesia were alleviated by MnO@TMNP, which was attributed to the reduced calcitonin gene-related peptide (CGRP) and substance P expression in the dorsal root ganglion and the downregulated Glial Fibrillary Acidic Protein (GFAP) and Fos Proto-Oncogene (c-FOS) signaling in the spinal cord. We confirmed that the MnO@TMNP nanomaterial alleviated the inflammatory immune microenvironment of intervertebral discs and the progression of disc degeneration, resulting in relieved discogenic pain.

An Engineered Bionic Nanoparticle Sponge as a Cytokine Trap and Reactive Oxygen Species Scavenger to Relieve Disc Degeneration and Discogenic Pain.

Steroid-induced osteonecrosis of the femoral head (SANFH) is a common hip joint disease that imposes a heavy economic burden on society. Patients continue to experience bone necrosis even after discontinuing glucocorticoid therapy, and the specific mechanisms require further investigation. The results of this study demonstrate that exosomes secreted by damaged vascular endothelial cells in SANFH lesions may be a crucial factor leading to abnormal adipogenic differentiation of bone marrow stromal cells (BMSCs). We also found that adipogenically differentiated BMSCs can secrete increased pro-inflammatory factors, which contribute to the maintenance of endothelial cell damage, thereby creating a vicious cycle. Due to endothelial damage and abnormal differentiation of BMSCs, insufficient bone repair occurs, leading to spontaneous disease progression. Based on our newly explored mechanism, we designed a nanomaterial, M-SiO@Icariin@EBHM, that simultaneously targets the repair of damaged vascular endothelium and re-regulation of BMSCs, and we assessed its role in delaying SANFH progression. We found that the M-SiO@Icariin@EBHM nanomaterial can target SANFH lesions when applied systemically, effectively clearing the elevated reactive oxygen species in vascular endothelial cells caused by glucocorticoids and regulating the osteogenic differentiation of BMSCs. This process breaks the vicious cycle while promoting bone repair and significantly inhibiting SANFH progression, revealing its potential as a promising treatment strategy for SANFH.

Dual-target nanotherapy for vascular endothelium and bone mesenchymal stem cells halt steroid-induced osteonecrosis of the femoral head progression.

 fusion gene variously activating autophagy in drug resistance of osteosarcoma: A novel gene fusion model report and mechanism research.

Osteosarcoma (OS) is a rapidly progressive primary malignant bone tumor that occurs in children and adolescents aged between 15 and 19 years and adults aged over 60 years. As alternative splicing (AS) changes caused by abnormal splicing factors contribute to tumor progression, gene expression and AS analyses were performed on 44 osteosarcoma patients to create a genome-wide co-expression network of RNA-binding proteins (RBPs), AS events, and AS genes. A gain- or loss-of-function osteosarcoma cell model was established, and an interactive network analysis and enrichment analysis were performed. Karyopherin Subunit Alpha 2 (KPNA2) negatively correlated with patient survival. KPNA2 transports splicing factor Y-box Binding Protein 1 (YBX1) into the nucleus and YBX1 accelerates the degradation of the ATP-dependent RNA helicase DDX3X (DDX3X) through the nonsense-mediated decay (NMD) pathway to promote intron retention of the DDX3X gene, thus reducing DDX3X protein levels. KPNA2/YBX1 axis regulates the stability of DDX3X mRNA and cell cycle progression. KPNA2/YBX1/DDX3X axis might be potential targets for inhibiting disease progression and improving OS patient survival. It integrates AS control of DDX3X into the progression of OS and represents a potential prognostic biomarker and therapeutic target for OS therapy.

KPNA2 promotes osteosarcoma progression by regulating the alternative splicing of DDX3X mediated by YBX1.

Osteosarcoma is a highly aggressive bone tumor with limited treatment options because of its drug resistance and tumor heterogeneity. In this study, we developed a multifunctional nanomaterial, P-FeO@Pal@HM, combining porous FeO nanoparticles, the DNA intercalator palmatine, and a hybrid membrane coating derived from osteosarcoma cells and tumor-associated endothelial cells. The FeO core facilitates a Fenton-like reaction, generating reactive oxygen species (ROS) to enhance DNA damage, whereas palmatine (Pal) inhibits RRM2 (ribonucleotide reductase regulatory subunit M2) expression, blocking DNA repair and inducing apoptosis. The hybrid membrane coating provides precise targeting of both tumor and endothelial cells, thus addressing the challenge of tumor heterogeneity. Under low-temperature photothermal conditions, the Fenton-like reaction is further enhanced, boosting ROS production and increasing cytotoxicity. This nanomaterial also modulates the immune microenvironment by promoting M1 macrophage polarization, thereby amplifying the antitumor immune response. P-FeO@Pal@HM demonstrated superior therapeutic efficacy to conventional treatments, significantly reducing tumor volume and inducing apoptosis with minimal toxicity to normal tissues. This innovative approach offers a promising strategy to overcome drug resistance, improve tumor targeting, and enhance treatment outcomes in osteosarcoma. The multifunctional design of P-FeO@Pal@HM highlights its potential as an advanced therapeutic platform in osteosarcoma.

Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal-Photodynamic-Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells.

Article	Year
De qi, a threshold of the stimulus intensity, elicits the specific response of acupoints and intrinsic change of human brain to acupuncture. Evidence-based complementary and alternative medicine : eCAM\| PubMed ID: 25228908	2014
Rare Bone Metastasis of Neuroendocrine Tumors of Unknown Origin: A Case Report and Literature Review. Orthopaedic surgery\| PubMed ID: 35856167	2022
Application and prospect of ROS-related nanomaterials for orthopaedic related diseases treatment. Frontiers in chemistry\| PubMed ID: 36277336	2022
Research progress of bone metastases: From disease recognition to clinical practice. Frontiers in oncology\| PubMed ID: 36761418	2022
An Engineered Bionic Nanoparticle Sponge as a Cytokine Trap and Reactive Oxygen Species Scavenger to Relieve Disc Degeneration and Discogenic Pain. ACS nano\| PubMed ID: 38237054	2024
Dual-target nanotherapy for vascular endothelium and bone mesenchymal stem cells halt steroid-induced osteonecrosis of the femoral head progression. Journal of controlled release : official journal of the Controlled Release Society\| PubMed ID: 39761861	2025
fusion gene variously activating autophagy in drug resistance of osteosarcoma: A novel gene fusion model report and mechanism research. Genes & diseases\| PubMed ID: 39877461	2025
KPNA2 promotes osteosarcoma progression by regulating the alternative splicing of DDX3X mediated by YBX1. Oncogene\| PubMed ID: 40216969	2025
Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal-Photodynamic-Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells. ACS nano\| PubMed ID: 40834268	2025

Qing Pan

Biography

JoVE Journal Publications

Other Publications